$VXRT

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Vaxart, Inc. ( OTCQX: VXRT ) ( "Vaxart" or the "Company" ) , a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn ...

Original reporting
GlobeNewswire · Vaxart, Inc.
Published Sep 19, 2025, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 20, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vaxart Announces Withdrawal of Reverse Stock Split Proposal — source image
Decision brief

The 30-second read

$VXRTNeutralLow
01

Why it matters

The withdrawal may reduce uncertainty and could be viewed positively by investors seeking stability.

02

Market read

The news is specific to Vaxart and has limited immediate impact on the broader market or sector.

03

What to watch

Market conditions and broader biotech sector trends could influence Vaxart's stock movement more than this specific news.

Timing: short-term

Background

Vaxart had proposed a reverse stock split to potentially improve share price and market perception.

Company-level read

Ticker impact

$VXRTNeutralMedium confidence
Context

The news pertains directly to Vaxart Inc., a biotech company developing oral vaccines, which is relevant for biotech and healthcare investors.

Expected impact

Minimal short-term impact; potential stabilization of stock price.

Evidence & confidence

The news is company-specific and indicates a strategic decision rather than a fundamental change; market reaction may be limited but could stabilize recent volatility.

Market effects

Limited impact on the biotech sector; no significant sector-wide movement expected.

Negligible regional effects; news is company-specific.

Low; primarily relevant to Vaxart investors and biotech sector watchers.

Counterpoint

Some traders might interpret the withdrawal as a sign of underlying issues or management uncertainty, potentially leading to caution.

Key entities

  • Vaxart, Inc.

    A clinical-stage biotechnology company developing oral recombinant vaccines.

Related articles

$VXRTMed

Vaxart, Inc. (VXRT): Results of Operations and Financial Condition

Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1000406.htm EXHIBIT 99.1 ex_1000406.htm Exhibit 99.1 Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety c

$VXRTMed

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Vaxart said it modified its BARDA funding contract via Advanced Technology International to match the current scope of its Phase 2b COVID-19 oral pill vaccine trial. Total available funding is now about $345 million, down ~$116 million after a BARDA partial termination reduced enrollment. The change releases ~$29 million to complete trial and exploratory analyses, enabling 12-month sentinel-cohort data in coming weeks and main-cohort data in 1H 2027.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.